寡转移灶立体定向消融放疗后局部控制:OligoCare 队列中期分析
OligoCare 是 EORTC-ESTRO E2-RADIatE 前瞻性观察登记研究,纳入 2,805 例前列腺、乳腺、结直肠及 NSCLC 寡转移患者,其中 2,447 例来自 57 家机构并接受推荐方案治疗(中位随访 31 个月)。1 年和 3 年局部进展率分别为 5.0% 和 11.4%;单病灶患者中 PTV 最低剂量是局部控制的唯一独立预测因素(每增加 10 Gy EQD2,风险降低 11%)。
要点
- 1 年与 3 年局部进展率分别为 5.0% 与 11.4%。
- 单病灶患者中 PTV 最低剂量越高,局部控制越好。
- 结直肠原发灶局部进展风险显著高于前列腺癌。
核心结论
- SABR 在寡转移疾病中可获得持久的真实世界局部控制,优化 PTV 最低剂量可能是最关键的技术因素。
- 结直肠转移灶局部控制较差,提示治疗强度挑战与内在放射抵抗可能共同作用,可指导未来试验设计与剂量提升策略。
研究设计与样本
- OligoCare 为前瞻性观察登记研究(EORTC-ESTRO E2-RADIatE),评估前列腺、乳腺、结直肠及 NSCLC 寡转移的 SABR。
- 2019 年 7 月至 2025 年 7 月共入组 2,805 例合格患者,其中 57 家机构的 2,447 例接受推荐方案治疗并纳入分析,中位随访 31 个月。
- 局部进展定义为 PTV 内复发,死亡按竞争风险处理;在患者水平和病灶水平(限单病灶患者)进行多因素分析。
主要发现
- 原发肿瘤分布为前列腺 41.7%、NSCLC 21.7%、结直肠 21.2%、乳腺 15.4%。
- 1 年和 3 年局部进展率分别为 5.0% 和 11.4%。
- 单病灶患者(n=1,714)中,PTV 最低剂量是局部控制的唯一独立预测因素,每增加 10 Gy EQD2 风险降低 11%(HR 0.89 [97.5% CI 0.82-0.98],p=0.005)。
- 患者水平分析中,新发寡转移(de novo OMD)较重复寡转移局部控制更好(HR 0.65 [97.5% CI 0.47-0.91],p=0.004),但该效应主要由新发病例接受更高剂量所致。
- 结直肠原发灶进展风险显著高于前列腺癌(HR 2.63 [97.5% CI 1.71-4.05],p<0.001),尽管其每分次剂量最高。
关键数值与推荐
- 局部进展定义:计划靶区(PTV)内复发,死亡作为竞争风险处理。
- 单病灶患者中 PTV 最低剂量每增加 10 Gy EQD2,局部进展风险降低 11%(HR 0.89 [97.5% CI 0.82-0.98],p=0.005)。
- 结直肠原发灶对比前列腺癌的局部进展 HR 为 2.63(97.5% CI 1.71-4.05,p<0.001)。
临床怎么用
- SABR 用于寡转移患者可获得较好的真实世界局部控制,应重视 PTV 最低剂量等剂量学参数。
- 对结直肠寡转移灶应考虑其局部控制较差,可能需要更积极的剂量或治疗强度策略。
- 新发与重复寡转移的局部控制差异可能受剂量影响,解读时需结合实际投照剂量。
局限性
- 本文为中期分析,随访时间有限。
- 为前瞻性观察登记研究,非随机对照设计,存在混杂因素。
- 病灶水平分析仅限于单病灶患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate real-world local control outcomes and identify clinical and dosimetric determinants of local progression following metastasis-directed stereotactic ablative radiotherapy (SABR) within the international OligoCare cohort. METHODS: OligoCare is a prospective observational registry (EORTC-ESTRO E2-RADIatE) evaluating SABR for oligometastatic prostate, breast, colorectal, and non-small cell lung cancer (NSCLC). The secondary endpoint, local progression, was defined as recurrence within the planning target volume (PTV), with death treated as a competing risk. Multivariate analyses were performed at both the patient and lesions levels (restricted to single-lesion patients) to account for confounding factors. RESULTS: Between July 2019 and July 2025, 2,805 eligible patients were enrolled. Of these, 2,447 from 57 institutions received the recommended protocol treatment and were included in the analysis (median follow-up 31 months). The distribution of primary tumors was prostate (41.7%), NSCLC (21.7%), colorectal (21.2%), and breast (15.4%). The 1- and 3-year local progression rates were 5.0% and 11.4%, respectively. Among single-lesion patients (n = 1,714), a higher PTV minimum dose was the sole independent predictor of local control, with an 11% risk reduction per 10 Gy EQD2 increase (HR 0.89 [97.5% CI 0.82-0.98], p = 0.005). Although de novo OMD showed better local control compared to repeat OMD in the patient-level analysis (HR0.65 [97.5% CI 0.47-0.91], p = 0.004), this effect was largely driven by higher dose delivery in de novo cases. Colorectal primaries faced a significantly higher risk of progression than prostate cancer (HR 2.63 [97.5% CI 1.71-4.05], p < 0.001), despite receiving the highest dose per fraction. CONCLUSION: SABR provides durable real-world local control in oligometastatic disease. Optimizing the minimum PTV dose appears the most critical technical factor for success. The inferior local control observed in colorectal metastases suggests a combination of treatment intensity challenges and intrinsic radioresistance, which could guide future trial design and dose-escalation strategies.
引用
- Joye I, Ricardi U, Scorsetti M, et al. Local control in oligometastatic cancer patients following metastasis-directed stereotactic ablative radiotherapy: An interim analysis of ESTRO EORTC E2-RADIatE OligoCare cohort. Radiother Oncol. 2026. PMID: 42019680. doi:10.1016/j.radonc.2026.111545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。